Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Makers Expect Greater Scrutiny By U.S. FDA

This article was originally published in PharmAsia News

Executive Summary

Recent actions by the U.S. FDA against three Indian drug makers have given the rest of India's pharmaceutical industry pause. They are concerned the agency is becoming more demanding of drugs exported from India to the United States. Behind the problem are FDA concerns about manufacturing deficiencies in India, a concern some Indian drug makers believe is likely to lead to more stringent review of even minor deficiencies. But Indian drug makers also are raising the question of whether the U.S. actions would amount to a "non-tariff barrier" to Indian-made drugs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts